PRGO(Perrigo Company plc) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $4.14B | $4.45B | $4.66B | $4.37B | $4.25B |
| 毛利润 | $1.42B | $1.46B | $1.68B | $1.54B | $1.49B |
| 营业利润 | $410.40M | $78.90M | $151.90M | $112.90M | −$1.12B |
| 净利润 | −$68.90M | −$140.60M | −$12.70M | −$171.80M | −$1.43B |
| 经营现金流 | $156.30M | $307.30M | $405.50M | $362.90M | $238.50M |
| 自由现金流 | $4.20M | $210.90M | $303.80M | $244.60M | $145.10M |
| 摊薄每股收益 | $-0.52 | $-1.04 | $-0.09 | $-1.25 | $-10.29 |